See more : Brookfield Business Corporation (BBUC.TO) Income Statement Analysis – Financial Results
Complete financial analysis of ICON Public Limited Company (ICLR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ICON Public Limited Company, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Changzheng Engineering Co.,LTD (603698.SS) Income Statement Analysis – Financial Results
- Almaden Minerals Ltd. (AMM.TO) Income Statement Analysis – Financial Results
- Value Partners Group Limited (0806.HK) Income Statement Analysis – Financial Results
- Lucky Harvest Co., Ltd. (002965.SZ) Income Statement Analysis – Financial Results
- FirstMark Horizon Acquisition Corp. (FMAC) Income Statement Analysis – Financial Results
ICON Public Limited Company (ICLR)
About ICON Public Limited Company
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.12B | 7.74B | 5.48B | 2.80B | 2.81B | 2.60B | 1.76B | 1.67B | 1.57B | 1.50B | 1.34B | 1.12B | 945.73M | 900.04M | 887.61M | 865.25M | 630.72M | 455.60M | 0.00 | 296.92M | 225.73M | 156.56M | 116.16M | 80.77M | 55.80M | 42.10M |
| Cost of Revenue | 5.72B | 5.53B | 3.97B | 1.99B | 1.97B | 1.83B | 1.03B | 961.33M | 908.98M | 903.17M | 845.41M | 718.13M | 611.92M | 541.39M | 507.78M | 489.24M | 354.48M | 256.26M | 0.00 | 162.56M | 122.37M | 83.37M | 63.80M | 42.04M | 29.30M | 0.00 |
| Gross Profit | 2.40B | 2.21B | 1.51B | 808.03M | 831.70M | 769.49M | 726.96M | 705.15M | 666.00M | 600.15M | 490.65M | 396.87M | 333.81M | 358.66M | 379.83M | 376.01M | 276.24M | 199.33M | 0.00 | 134.36M | 103.35M | 73.18M | 52.36M | 38.72M | 26.50M | 42.10M |
| Gross Profit Ratio | 29.56% | 28.60% | 27.52% | 28.89% | 29.64% | 29.64% | 41.34% | 42.31% | 42.29% | 39.92% | 36.72% | 35.59% | 35.30% | 39.85% | 42.79% | 43.46% | 43.80% | 43.75% | 0.00% | 45.25% | 45.79% | 46.75% | 45.08% | 47.94% | 47.49% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 319.28M | 317.00M | 318.56M | 322.27M | 332.90M | 308.74M | 277.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.52M | 6.74M | 7.17M | 4.51M | 3.56M | 5.20M | 3.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 776.36M | 778.75M | 585.33M | 341.69M | 336.75M | 325.79M | 323.74M | 325.73M | 326.79M | 336.46M | 313.93M | 280.78M | 255.86M | 232.69M | 230.91M | 248.78M | 187.99M | 136.57M | 0.00 | 88.81M | 71.12M | 48.95M | 36.31M | 27.35M | 18.00M | 0.00 |
| Other Expenses | 667.72M | 569.51M | 314.99M | 74.38M | 61.55M | 65.92M | 61.30M | 59.58M | 57.68M | 52.54M | 46.51M | 42.82M | 38.68M | 33.87M | 41.47M | 27.73M | 19.01M | 14.95M | 0.00 | 11.17M | 7.31M | 6.02M | 4.98M | 3.23M | 2.00M | 0.00 |
| Operating Expenses | 1.44B | 1.35B | 900.32M | 416.07M | 398.30M | 392.37M | 395.02M | 385.30M | 384.46M | 389.00M | 360.45M | 327.30M | 294.55M | 266.56M | 272.38M | 276.51M | 207.00M | 151.52M | 0.00 | 99.98M | 78.42M | 54.97M | 41.29M | 30.58M | 20.00M | 0.00 |
| Cost & Expenses | 7.16B | 6.88B | 4.87B | 2.41B | 2.37B | 2.22B | 1.43B | 1.35B | 1.29B | 1.29B | 1.21B | 1.05B | 906.47M | 807.95M | 780.16M | 765.74M | 561.48M | 407.78M | 0.00 | 262.54M | 200.80M | 138.34M | 105.09M | 72.62M | 49.30M | 0.00 |
| Interest Income | 5.01M | 2.35M | 574.00K | 2.72M | 6.86M | 4.76M | 2.35M | 1.48M | 1.31M | 1.15M | 986.00K | 1.15M | 1.19M | 1.76M | 752.00K | 2.88M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 336.70M | 229.73M | 182.42M | 15.07M | 6.42M | 13.61M | 12.99M | 13.01M | 3.99M | 785.00K | 1.29M | 1.97M | 1.64M | 1.13M | 3.53M | 4.11M | 0.00 | 0.00 | 0.00 | 281.00K | 0.00 | 0.00 | 0.00 | 575.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 585.95M | 614.73M | 360.33M | 94.61M | 91.92M | 65.92M | 61.25M | 59.58M | 57.68M | 52.54M | 46.51M | 42.82M | 38.68M | 33.87M | 32.66M | 27.73M | 18.89M | 14.84M | 0.00 | 10.60M | 7.27M | 5.97M | 4.96M | 3.23M | 2.00M | 0.00 |
| EBITDA | 1.52B | 1.41B | 739.43M | 488.83M | 532.19M | 451.76M | 401.94M | 379.43M | 339.21M | 263.69M | 168.67M | 111.09M | 69.32M | 127.73M | 140.86M | 130.11M | 88.25M | 62.77M | 0.00 | 31.94M | 45.55M | 32.23M | 24.23M | 16.05M | 8.50M | 42.10M |
| EBITDA Ratio | 18.74% | 18.57% | 16.85% | 17.48% | 17.64% | 17.22% | 19.33% | 23.26% | 21.54% | 18.13% | 13.90% | 10.18% | 9.28% | 14.00% | 15.87% | 15.04% | 13.99% | 13.78% | 0.00% | 15.34% | 14.28% | 15.48% | 13.82% | 16.09% | 15.23% | 100.00% |
| Operating Income | 956.15M | 795.24M | 608.47M | 391.97M | 433.41M | 377.12M | 331.95M | 311.69M | 281.54M | 202.35M | 121.17M | 69.57M | 29.44M | 92.10M | 107.45M | 99.50M | 69.24M | 47.82M | 0.00 | 34.38M | 24.93M | 18.21M | 11.08M | 8.15M | 6.50M | 42.10M |
| Operating Income Ratio | 11.78% | 10.27% | 11.10% | 14.01% | 15.45% | 14.53% | 18.88% | 18.70% | 17.88% | 13.46% | 9.07% | 6.24% | 3.11% | 10.23% | 12.11% | 11.50% | 10.98% | 10.50% | 0.00% | 11.58% | 11.04% | 11.63% | 9.53% | 10.09% | 11.65% | 100.00% |
| Total Other Income/Expenses | -331.69M | -227.39M | -181.85M | -10.30M | -6.42M | -8.74M | -10.28M | -11.52M | -2.69M | 366.00K | -302.00K | -796.00K | -448.00K | 629.00K | -2.78M | -1.22M | 2.74M | 3.64M | 0.00 | 979.00K | -9.10M | -5.60M | -4.62M | 2.52M | 2.60M | -32.49M |
| Income Before Tax | 624.47M | 567.85M | 196.68M | 382.18M | 426.99M | 368.38M | 327.67M | 300.17M | 278.85M | 202.72M | 120.87M | 68.70M | 29.00M | 92.72M | 104.67M | 98.28M | 71.98M | 51.46M | 0.00 | 34.67M | 25.28M | 19.33M | 13.60M | 9.19M | 9.10M | 0.00 |
| Income Before Tax Ratio | 7.69% | 7.34% | 3.59% | 13.66% | 15.22% | 14.19% | 18.63% | 18.01% | 17.71% | 13.48% | 9.05% | 6.16% | 3.07% | 10.30% | 11.79% | 11.36% | 11.41% | 11.29% | 0.00% | 11.68% | 11.20% | 12.35% | 11.70% | 11.38% | 16.31% | 0.00% |
| Income Tax Expense | 11.75M | 59.41M | 41.33M | 50.75M | 51.13M | 45.56M | 54.72M | 37.99M | 39.31M | 30.25M | 18.05M | 10.36M | 6.12M | 5.65M | 10.38M | 19.97M | 15.83M | 12.92M | 0.00 | 8.93M | 7.00M | 5.13M | 2.62M | 3.12M | 1.60M | 38.20M |
| Net Income | 612.34M | 505.30M | 153.19M | 327.81M | 373.99M | 322.82M | 272.94M | 262.18M | 239.54M | 172.47M | 102.81M | 58.35M | 22.88M | 87.07M | 94.30M | 78.12M | 55.96M | 38.30M | 0.00 | 25.74M | 18.28M | 14.20M | 10.98M | 6.07M | 7.50M | 3.90M |
| Net Income Ratio | 7.54% | 6.53% | 2.79% | 11.72% | 13.33% | 12.44% | 15.52% | 15.73% | 15.21% | 11.47% | 7.70% | 5.23% | 2.42% | 9.67% | 10.62% | 9.03% | 8.87% | 8.41% | 0.00% | 8.67% | 8.10% | 9.07% | 9.45% | 7.51% | 13.44% | 9.26% |
| EPS | 7.46 | 6.20 | 2.28 | 6.29 | 6.94 | 5.96 | 5.04 | 4.75 | 4.08 | 2.80 | 1.69 | 0.97 | 0.38 | 1.46 | 1.61 | 1.34 | 1.95 | 1.35 | 0.00 | 1.94 | 1.55 | 1.22 | 0.97 | 0.55 | 0.69 | 0.28 |
| EPS Diluted | 7.40 | 6.13 | 2.25 | 6.24 | 6.88 | 5.90 | 4.98 | 4.65 | 3.97 | 2.73 | 1.65 | 0.96 | 0.37 | 1.44 | 1.57 | 1.30 | 1.88 | 1.33 | 0.00 | 1.88 | 1.50 | 1.16 | 0.92 | 0.51 | 0.63 | 0.25 |
| Weighted Avg Shares Out | 82.10M | 81.53M | 67.11M | 52.86M | 53.86M | 54.12M | 54.13M | 55.25M | 58.75M | 61.50M | 60.91M | 59.97M | 60.38M | 59.72M | 58.64M | 58.25M | 28.71M | 28.31M | 13.86M | 13.27M | 11.81M | 11.66M | 11.29M | 11.05M | 10.91M | 13.93M |
| Weighted Avg Shares Out (Dil) | 82.72M | 82.47M | 68.07M | 53.28M | 54.33M | 54.74M | 54.87M | 56.41M | 60.29M | 63.13M | 62.25M | 60.68M | 61.07M | 60.64M | 59.90M | 60.22M | 29.75M | 28.86M | 13.86M | 13.70M | 12.18M | 12.24M | 11.94M | 11.82M | 11.92M | 15.92M |
Eight stock picks in AI, obesity drugs, e-commerce and other growth areas beyond the S&P 500
It is understandable for U.S. investors to be focused on the largest technology companies that have driven such strong performance for the S&P 500 over the past decade. But learning about strategies that give exposure beyond the U.S. large-cap benchmark...
Icon PLC (ICLR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ICLR or CRL: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical Services sector might want to consider either Icon PLC (ICLR) or Charles River Laboratories (CRL). But which of these two companies is the best option for those looking for undervalued stocks?
ICON Announces CFO Transition
DUBLIN--(BUSINESS WIRE)--ICON Announces CFO Transition.
Recent Price Trend in Icon PLC (ICLR) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Icon PLC (ICLR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
ICON plc Schedules First Quarter 2024 Earnings Conference Call
DUBLIN--(BUSINESS WIRE)--ICON plc Schedules First Quarter 2024 Earnings Conference Call.
ICON (ICLR) Up 7.6% Since Last Earnings Report: Can It Continue?
ICON (ICLR) reported earnings 30 days ago. What's next for the stock?
Icon PLC (ICLR) Is a Great Choice for 'Trend' Investors, Here's Why
Icon PLC (ICLR) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
ICLR vs. DOCS: Which Stock Is the Better Value Option?
Investors with an interest in Medical Services stocks have likely encountered both Icon PLC (ICLR) and Doximity (DOCS). But which of these two companies is the best option for those looking for undervalued stocks?
3 Medical Services Stocks to Buy as Industry Trends Improve
The Zacks Medical - Services industry is growing on digital healthcare adoption. ELV, COR and ICLR are set to gain the most.
Source: https://incomestatements.info
Category: Stock Reports